Malaysia Launches Roadmap To Become Vaccine Development Hub
Through NVDR and MGVI, Malaysia will produce quality vaccines with safety conditions set by the National Pharmaceutical Regulatory Agency (NPRA), said the Prime Minister. He also said that while the R&D will require heavy investment, it will bring long-term returns in the form of cost savings in treating diseases, as well as producing high-skill human capital in healthcare research fields. There are currently three projects in development, with the first involving two types of COVID-19 vaccines, one that is inactivated and another that uses mRNA technology, which were announced back in June....